Chitogel has developed bioresorbable dressings to improve surgical outcomes and patient wellbeing post-functional endoscopic sinus surgery (FESS). Utilising the well established wound dressing derivative, chitosan, Chitogel has developed a compound which is clinically proven to reduce adverse events in post-FESS sites, and improve patient outcomes, across all clinically relevant criteria.

Based in Wellington, Chitogel has developed a strong relationship with the global medical device company, Medtronic, which has enabled early international sales and quick adoption by ENT clinicians and KOLs.